Related Read: 14 Peptides Are About to Become Legal Again What This Means for Your Health What the science says about peptide stacking as a category 1) Combination trials are the exception, not the rule For many popular peptides, we have: mechanistic arguments small studies (sometimes in narrow contexts) preclinical work We rarely have: well-powered, long-term human trials on the combination hard outcomes (function, cardiometabolic endpoints, durability, safety) 2) Stacking amplifies the two biggest risks in this space Quality risk (variable purity, contamination, labeling issues) Physiology risk (more pathways affected, more unintended effects) 3) The GH/IGF-1 axis is where stacking gets most clinically delicate CJC-1295 has human data showing it raises GH/IGF-1
Supports gut barrier integrity and digestive resilience
Gastric protection is where BPC-157 was first identified
Biz Opps: DoD SBIR 22.4 Annual BAA Topic Open DARPA HR0011SB20224-04, HR0011SB20224-05, HR0011SB20224-06 Wednesday, May 11, 2022 The Department of Defense announces the opening of the following Broad Agency Announcement (BAA) topics: DARPA HR0011SB20224-04: Innovative Fabrication Techniques for Millimeter-wave Linear Beam Vacuum Electron Devices HR0011SB20224-05: Readout Integrated Circuit Development for 2-micron Cutoff Linear Mode Staircase Avalanche Photodiodes HR0011SB20224-06: Hardening Aircraft Systems through Hardware (HASH) Full topic descriptions and instructions are available on DSIP at and at IMPORTANT DATES: May 11, 2022 : Topics open, begin submitting proposals in DSIP June 7, 2022 : Topic Q&A closes to new questions at 12:00 p.m
The next morning, I drive to 10Squared for my VO2 max test and a couple of strength assessments
